Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Nov 2017 Status changed from recruiting to discontinued.
- 26 Aug 2013 New trial record